Cresset Asset Management’s bluebird bio BLUE Stock Holding History

Cresset Asset Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,276	Closed	-$255K	–	1007
2021 Q4	$255K	Sell	1,276 -41	-3%	-$9.68K	﹤0.01%	941
2021 Q3	$326K	Buy	1,317 +542	+70%	+$155K	﹤0.01%	810
2021 Q2	$322K	Buy	+775	New	+$307K	﹤0.01%	735
2019 Q2	–	Hold	0	–	-$1K	–	626
2019 Q1	–	Hold	0	–	–	–	1763

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Cresset Asset Management's BLUE Position: Q1 2022 in Review

Cresset Asset Management sold out of bluebird bio (BLUE) in Q1 2022, closing a stake of 1,276 shares — an estimated $255K sold.

Cresset Asset Management first reported a position in BLUE in Q2 2021 and held it in 3 quarters. The position peaked at $326K in Q3 2021. 174 funds tracked by Wall St. Rank hold BLUE as of Q1 2022.

Cresset Asset Management reported no remaining bluebird bio position as of Q1 2022 after selling out during the quarter.
Cresset Asset Management sold 1,276 bluebird bio shares in Q1 2022, an estimated $255K.
Cresset Asset Management first reported a position in bluebird bio in Q2 2021 and held it in 3 quarters.
Cresset Asset Management's bluebird bio position peaked at $326K in Q3 2021.
174 funds tracked by Wall St. Rank held bluebird bio as of Q1 2022.

Based on Cresset Asset Management's 13F filing for Q1 2022, filed 16 May 2022.